{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:55:47Z","timestamp":1792785347857,"version":"4.5.0"},"reference-count":37,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2023,8,27]],"date-time":"2023-08-27T00:00:00Z","timestamp":1693094400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2023,8,27]],"date-time":"2023-08-27T00:00:00Z","timestamp":1693094400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"funder":[{"name":"Myovant Sciences GmbH","id":[{"id":"https:\/\/ror.org\/04p31sb09","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Gynecological Endocrinology"],"published-print":{"date-parts":[[2023,12,14]]},"DOI":"10.1080\/09513590.2023.2249107","type":"journal-article","created":{"date-parts":[[2023,8,27]],"date-time":"2023-08-27T19:01:01Z","timestamp":1693162861000},"update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":2,"title":["Relugolix combination therapy in European women with symptomatic uterine fibroids: a subgroup analysis from the randomized phase 3 LIBERTY pivotal trials"],"prefix":"10.1080","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1359-770X","authenticated-orcid":false,"given":"Roberta","family":"Venturella","sequence":"first","affiliation":[{"name":"Department of Clinical and Experimental Medicine, Unit of Obstetrics and Gynecology, Magna Graecia University of Catanzaro","place":["Catanzaro, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4138-332X","authenticated-orcid":false,"given":"Tomasz","family":"Rechberger","sequence":"additional","affiliation":[{"name":"Second Department of Gynecology, Medical University of Lublin","place":["Lublin, Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e1nos","family":"Zatik","sequence":"additional","affiliation":[{"name":"Szent Anna Women\u2019s OB\/GYN and Ultrasound Outpatient Clinic","place":["Debrecen, Hungary"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel B.","family":"Wagman","sequence":"additional","affiliation":[{"name":"Clinical Research, Sumitomo Pharma America, Inc","place":["Brisbane, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Zhu","sequence":"additional","affiliation":[{"name":"Development Operation, Sumitomo Pharma America, Inc","place":["Brisbane, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-0324-9239","authenticated-orcid":false,"given":"Viatcheslav G.","family":"Rakov","sequence":"additional","affiliation":[{"name":"Research and Development, Myovant Sciences GmbH","place":["Basel, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8851-625X","authenticated-orcid":false,"given":"Felice","family":"Petraglia","sequence":"additional","affiliation":[{"name":"Department of Experimental, Clinical and Biomedical Sciences, Obstetrics and Gynecology, University of Florence, Careggi University Hospital","place":["Florence, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2023,8,27]]},"reference":[{"key":"e_1_3_5_2_1","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0000000000002785"},{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1067\/mob.2003.99"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1089\/jwh.2018.7076"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1701-2163(15)30338-8"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.2147\/CEOR.S139335"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6874-12-6"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.12172.1"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1607264"},{"key":"e_1_3_5_10_1","unstructured":"Agency for Healthcare Research and Quality. Management of uterine fibroids. Comparative effectiveness review no. 195. Rockville (MD): Agency for Healthcare Research and Quality (US) [Internet]; 2017 [cited 2021 Nov]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK537742\/"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1736"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/2414609"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2020.07.028"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2013.12.001"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2008283"},{"key":"e_1_3_5_16_1","unstructured":"European Medicines Agency. Ryeqo (40\u2009mg relugolix 1\u2009mg estradiol (as hemihydrate) and 0.5\u2009mg norethisterone acetate). Summary of product characteristics; 2023 [cited 2023 Jul]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/ryeqo-epar-product-information_en.pdf"},{"key":"e_1_3_5_17_1","unstructured":"US Food and Drug Administration. Myfembree (relugolix estradiol norethindrone acetate) prescribing information; 2023 [updated 2023 Jul; cited Sep 2022]. Available from: https:\/\/www.myfembree.com\/static\/myfembree-prescribing-information.pdf"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2019.09.1237"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1208930"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/his.12039"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00438-014-0938-x"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.1500463"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20246151"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1097\/GRF.0000000000000164"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0033-1348896"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2015.09.032"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1103182"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1103180"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2014.02.008"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0000000000003141"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12905-021-01475-2"},{"issue":"4","key":"e_1_3_5_32_1","first-page":"133","article-title":"Ulipristal acetate as a treatment option for uterine fibroids","volume":"16","author":"Piecak K","year":"2017","unstructured":"Piecak K, Milart P, Wo\u017aniakowska E, et\u00a0al. Ulipristal acetate as a treatment option for uterine fibroids. Prz Menopauzalny. 2017;16(4):133\u2013136.","journal-title":"Prz Menopauzalny"},{"key":"e_1_3_5_33_1","unstructured":"European Medicines Agency. Ulipristal acetate (Esmya). Summary of product characteristics; 2023 [updated 2023 Jul; cited Aug 2021]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/esmya-epar-product-information_en.pdf"},{"key":"e_1_3_5_34_1","unstructured":"US Food and Drug Administration. Oriahnn (elagolix estradiol and norethindrone acetate capsules; elagolix capsules) prescribing information; 2023 [updated 2023 Jul; cited 2021 Oct]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/213388s000lbl.pdf"},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2017-01875"},{"key":"e_1_3_5_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2020.09.016"},{"key":"e_1_3_5_37_1","unstructured":"European Medicines Agency. Linzagolix choline (Yselty). Summary of product characteristics; 2022 [cited 2023 Jul]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/yselty-epar-product-information_en.pdf"},{"key":"e_1_3_5_38_1","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0000000000004988"}],"container-title":["Gynecological Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/09513590.2023.2249107","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/09513590.2023.2249107","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/09513590.2023.2249107","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T09:49:12Z","timestamp":1792144152000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/09513590.2023.2249107"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,27]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,12,14]]}},"alternative-id":["10.1080\/09513590.2023.2249107"],"URL":"https:\/\/doi.org\/10.1080\/09513590.2023.2249107","relation":{},"ISSN":["0951-3590","1473-0766"],"issn-type":[{"value":"0951-3590","type":"print"},{"value":"1473-0766","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,27]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=igye20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=igye20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-01-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-07-31","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-08-09","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-08-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"2249107"}}